Business Roundup

Resonac Holdings has carved out its petrochemical arm as a stand-alone company, Crasus Chemical, to prepare it for a split next year. The petrochemical business generates about 20% of the Japanese firm’s sales.

GSK has agreed to license UK drug services firm Touchlight’s technology called doggybone DNA, which enables the development and production of products based on messenger RNA (mRNA). GSK says access to Touchlight’s product will allow it to make multivalent mRNA vaccines against seasonal epidemics and pandemic threats.

SK Innovation, which operates a large petrochemical business, plans to merge with the energy firm SK E&S. Both South Korean firms originally operated as part of the same company until 1999, when SK E&S was separated out to form SK-Enron.

Indorama Ventures expects to spin off Indovinya in 2026. The surfactants company was formed through purchases of businesses from Huntsman and of the Brazilian specialty chemical maker Oxiteno.

Messer Group plans to build a 10 MW green hydrogen plant at an industrial park in Jülich, Germany. The plant’s elecrolyzers will be able to produce up to 180 kg of H₂per hour, primarily for fuel cell buses.

Eurofins CDMO Alphora says it has expanded its drug active manufacturing facility in Mississauga, Ontario. The company has added nearly 1,400 m²of processing and warehousing space as well as new reactors to its setup.

Kurita America will work with the start-up Solugen to develop carbon-negative industrial water-treatment products that replace phosphorus- and petroleum- based additives. Solugen’s chemienzymatic process turns corn sugar into hydrogen peroxide and organic acids.

AcceleDev Chemical, a New Jersey–based firm that provides chemical raw materials and chemical synthesis services, has opened a 460 m²R&D and production facility in Cranbury. The expansion will increase the company’s ability to make drug actives.